📊 CPRX Key Takeaways
Investment Thesis
Catalyst Pharmaceuticals demonstrates exceptional financial health with robust profitability (36.4% net margin, 43.8% operating margin), strong revenue growth of 19.8% YoY, and exceptional cash generation (35.4% FCF margin on $208.6M). The company maintains fortress-like balance sheet strength with $709.2M cash, zero debt, and a 6.08x current ratio, providing significant financial flexibility for growth investments or shareholder returns.
CPRX Strengths
- Outstanding profitability with 36.4% net margin and 43.8% operating margin, indicating strong pricing power and operational efficiency
- Exceptional free cash flow generation of $208.6M (35.4% margin) with minimal capital requirements ($58K CapEx), demonstrating capital-light business model
- Fortress balance sheet with $709.2M cash, zero long-term debt, and 6.08x current ratio providing maximum financial flexibility
- Strong earnings growth with diluted EPS up 28.2% YoY despite flat net income, indicating effective capital management
- Healthy revenue growth of 19.8% YoY in pharmaceutical sector demonstrates sustained market demand and competitive positioning
- High ROE of 22.5% and ROA of 19.4% indicate efficient capital deployment and strong asset utilization
CPRX Risks
- Pharmaceutical sector is highly regulated with risks of patent expiration, FDA regulatory changes, or clinical trial failures affecting future revenue
- Concentrated business model typical of specialty pharma companies creates revenue concentration risk if key products face competition or obsolescence
- Limited disclosure on gross margin breakdown suggests potential reliance on specific high-margin products vulnerable to market dynamics
- The flat net income growth (0.0% YoY) despite 19.8% revenue growth suggests potential operating expense increases or margin compression headwinds
- 12 Form 4 insider filings in 90 days warrants monitoring for potential significant insider transactions or strategic shifts
Key Metrics to Watch
- Revenue growth sustainability and year-over-year growth rate trends to confirm 19.8% growth trajectory
- Operating margin and net margin trends to detect any profitability compression or operational challenges
- Free cash flow generation consistency to ensure $208.6M level is sustainable versus one-time benefits
- Product pipeline and market share dynamics given pharmaceutical sector competitive pressures
- Cash deployment strategy to understand capital allocation priorities (M&A, R&D, shareholder returns)
- Insider transaction patterns and any significant management changes indicated by Form 4 filings
CPRX Financial Metrics
💡 AI Analyst Insight
The 35.4% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 6.08x current ratio provides a solid financial cushion.
CPRX Profitability Ratios
CPRX vs Healthcare Sector
How CATALYST PHARMACEUTICALS, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CPRX Balance Sheet & Liquidity
CPRX 5-Year Financial Trend
5-Year Trend Summary: CATALYST PHARMACEUTICALS, INC.'s revenue has grown significantly by 318% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.63 reflects profitable operations.
CPRX Growth Metrics (YoY)
CPRX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $128.7M | $23.3M | $0.35 |
| Q2 2025 | $122.7M | $23.3M | $0.33 |
| Q1 2025 | $98.5M | $23.3M | $0.19 |
| Q3 2024 | $102.7M | $23.3M | $-0.29 |
| Q2 2024 | $99.6M | $23.3M | $0.33 |
| Q1 2024 | $85.4M | $23.3M | $0.19 |
| Q3 2023 | $57.2M | $13.2M | $0.20 |
| Q2 2023 | $53.1M | $13.2M | $0.20 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CPRX Capital Allocation
CPRX SEC Filings
Access official SEC EDGAR filings for CATALYST PHARMACEUTICALS, INC. (CIK: 0001369568)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CPRX
What is the AI rating for CPRX?
CATALYST PHARMACEUTICALS, INC. (CPRX) has an AI rating of STRONG BUY with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CPRX's key strengths?
Outstanding profitability with 36.4% net margin and 43.8% operating margin, indicating strong pricing power and operational efficiency. Exceptional free cash flow generation of $208.6M (35.4% margin) with minimal capital requirements ($58K CapEx), demonstrating capital-light business model.
What are the risks of investing in CPRX?
Pharmaceutical sector is highly regulated with risks of patent expiration, FDA regulatory changes, or clinical trial failures affecting future revenue. Concentrated business model typical of specialty pharma companies creates revenue concentration risk if key products face competition or obsolescence.
What is CPRX's revenue and growth?
CATALYST PHARMACEUTICALS, INC. reported revenue of $589.0M.
Does CPRX pay dividends?
CATALYST PHARMACEUTICALS, INC. does not currently pay dividends.
Where can I find CPRX SEC filings?
Official SEC filings for CATALYST PHARMACEUTICALS, INC. (CIK: 0001369568) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CPRX's EPS?
CATALYST PHARMACEUTICALS, INC. has a diluted EPS of $1.68.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.